Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track ODTX with free AI briefings, catalyst countdowns, and dilution alerts.

ODTX

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$82M Cash on Hand

6.5mo Cash Runway

5.4% Short Interest

🧪 Upcoming Trial Catalysts

2026-04-01 · Phase 2 — Recruiting — Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Sev
2024-11-25 · Phase 1 — Results Expected — Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants

📊 Drug Pipeline

Drug	Indication	Phase	Status
OD-07656	Ulcerative Colitis (UC)	PHASE2	RECRUITING
Vedolizumab	Ulcerative Colitis (UC)	PHASE2	RECRUITING

💰 Cash Runway & Dilution Risk

ODTX holds $82M in cash and burns about $37.8M/quarter from operations, giving an estimated runway of 6.5 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for ODTX free →

Get the full ODTX picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for ODTX and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z